These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23264689)

  • 1. The future of USP monographs for PET drugs.
    Schwarz S; Norenberg J; Berridge M; Dragotakes S; Hung J; Link J; Mason NS; Mattmuller S; Nickel RA; Packard A; Paolino J; Petry N; Ponto J; Quinton TM; Seifert KL; Swanson D; Weiner RE; Zigler S
    J Nucl Med; 2013 Mar; 54(3):472-5. PubMed ID: 23264689
    [No Abstract]   [Full Text] [Related]  

  • 2. Current good manufacturing practices for PET drug products in the United States.
    Swanson D; Graham M; Heinonen TM; Libby P; Mills GQ
    J Nucl Med; 2009 Aug; 50(8):26N-8N. PubMed ID: 19652213
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA cGMP requirements for PET drugs.
    Norenberg JP; Schwarz S; VanBrocklin H
    J Nucl Med; 2011 May; 52(5):16N. PubMed ID: 21536923
    [No Abstract]   [Full Text] [Related]  

  • 4. Final PET CGMP regulation.
    Breslow K; Schwarz SW
    J Nucl Med; 2010 Mar; 51(3):15N-6N. PubMed ID: 20197439
    [No Abstract]   [Full Text] [Related]  

  • 5. Current good manufacturing practice for positron emission tomography drugs.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Dec; 74(236):65409-36. PubMed ID: 20169678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. USP and PET radiopharmaceuticals: 1997 FDAMA puts standard-setting body at center of regulatory process.
    Hung JC; Callahan RJ
    J Nucl Med; 2004 Jan; 45(1):13N-14N, 16N. PubMed ID: 14734661
    [No Abstract]   [Full Text] [Related]  

  • 7. USP general chapter <797> pharmaceutical compounding-sterile preparations.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):20N, 28N. PubMed ID: 15181114
    [No Abstract]   [Full Text] [Related]  

  • 8. The potential impact of usp general chapter <797> on procedures and requirements for the preparation of sterile radiopharmaceuticals.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):21N-6N. PubMed ID: 15181115
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of various requirements of the quality assurance procedures for (18)F-FDG injection.
    Hung JC
    J Nucl Med; 2002 Nov; 43(11):1495-506. PubMed ID: 12411554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CGMP for PET drugs: important steps to take now.
    Vanbrocklin H; Schwarz S
    J Nucl Med; 2010 Dec; 51(12):17N. PubMed ID: 21098789
    [No Abstract]   [Full Text] [Related]  

  • 11. Operation of a radiopharmacy for a clinical trial.
    Norenberg JP; Petry NA; Schwarz S
    Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is now current good manufacturing practice for PET drugs?
    Harolds J
    Clin Nucl Med; 2010 May; 35(5):329. PubMed ID: 20395704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The radioactive drug research committee: Background and retrospective study of reported research data (1975-2004).
    Suleiman OH; Fejka R; Houn F; Walsh M
    J Nucl Med; 2006 Jul; 47(7):1220-6. PubMed ID: 16818959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacy compounding: background on the latest federal initiatives.
    Nichols D
    J Nucl Med; 1998 Jan; 39(1):26N. PubMed ID: 9443726
    [No Abstract]   [Full Text] [Related]  

  • 15. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories.
    Jimenez FA
    Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of eINDs for evaluation of multiple related PET amyloid plaque imaging agents.
    Skovronsky D
    J Nucl Med; 2008 Jun; 49(6):47N-48N. PubMed ID: 18511825
    [No Abstract]   [Full Text] [Related]  

  • 17. Exemption of radiopharmaceuticals from <797>.
    Hung JC; VanBrocklin HF
    J Nucl Med; 2004 Oct; 45(10):14N. PubMed ID: 15551510
    [No Abstract]   [Full Text] [Related]  

  • 18. Compounding pharmaceuticals for investigational use.
    Tamer HR; Sweet BV
    Am J Health Syst Pharm; 2002 Sep; 59(18):1716-9. PubMed ID: 12298108
    [No Abstract]   [Full Text] [Related]  

  • 19. From the SNM Committee on Pharmacopeia: Exemption of radiopharmaceuticals from <797>.
    Hung JC;
    J Nucl Med; 2004 Oct; 45(10):13N, 16N. PubMed ID: 15551509
    [No Abstract]   [Full Text] [Related]  

  • 20. How flexible is USP General Chapter <823>?
    Hung JC
    J Nucl Med; 2011 Jan; 52(1):14N-16N. PubMed ID: 21189411
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.